RAGE and Experimental Diabetic Neuropathy
暂无分享,去创建一个
W. Liu | A. Schmidt | M. Nguyen | D. Zochodne | L. Rong | C. Toth | Fei Song | V. Brussee | Christina Yang | José Martinez | N. Ramji | J. Durand | Jeff Durand
[1] P. Low,et al. Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury , 2006, Journal of the Neurological Sciences.
[2] S. Chung,et al. Aldose Reductase–Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage , 2006, Diabetes.
[3] D. Zochodne,et al. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes , 2006, Diabetologia.
[4] R. Pop-Busui,et al. Peripheral nerve dysfunction in experimental diabetes is mediated by cyclooxygenase-2 and oxidative stress. , 2005, Antioxidants & redox signaling.
[5] E. Schleicher,et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[6] J. Groves,et al. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] D. Zochodne,et al. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? , 2005, Diabetes.
[8] J. Schapansky,et al. Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[9] J. Schneider,et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.
[10] C. Yabe-Nishimura,et al. Neurotrophin‐3‐induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway , 2004, Journal of neurochemistry.
[11] Ling-Hao Li,et al. Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression Published, JLR Papers in Press, June 21, 2004. DOI 10.1194/jlr.M400169-JLR200 , 2004, Journal of Lipid Research.
[12] R. Ramasamy,et al. RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[13] S. Yagihashi,et al. Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. , 2004, Biochemical and biophysical research communications.
[14] C. Cheng,et al. Diabetes Mellitus and the Sensory Neuron , 2004, Journal of neuropathology and experimental neurology.
[15] S. Yagihashi,et al. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice , 2003, Journal of neurochemistry.
[16] S. Chung,et al. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress , 2003, Molecular and Cellular Neuroscience.
[17] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[18] A. Vinik,et al. Prevention of the complications of diabetes. , 2003, The American journal of managed care.
[19] B. Carter,et al. Activation of the transcription factor NF-κB in Schwann cells is required for peripheral myelin formation , 2003, Nature Neuroscience.
[20] H. Huttunen,et al. Receptor for Advanced Glycation End Products (RAGE) Signaling Induces CREB-dependent Chromogranin Expression during Neuronal Differentiation* , 2002, The Journal of Biological Chemistry.
[21] M. Cotter,et al. Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism , 2002, Diabetes/metabolism research and reviews.
[22] J. Mamputu,et al. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. , 2002, Journal of diabetes and its complications.
[23] H. Brismar,et al. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. , 2002, Kidney international.
[24] C. Lacroix,et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients , 2002, Journal of Neurology.
[25] J. Wautier,et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. , 2002, Kidney international.
[26] S. Tripp,et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.
[27] C. Cheng,et al. Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. , 2001, Brain : a journal of neurology.
[28] J. Wautier,et al. Advanced glycation end products, their receptors and diabetic angiopathy. , 2001, Diabetes & metabolism.
[29] A. Heidland,et al. Advanced glycation end products and the progressive course of renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] M. Mattson,et al. Endoplasmic Reticulum d-myo-Inositol 1,4,5-Trisphosphate-sensitive Stores Regulate Nuclear Factor-κB Binding Activity in a Calcium-independent Manner* , 2001, The Journal of Biological Chemistry.
[31] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[32] G. Jerums,et al. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.
[33] H. Huttunen,et al. Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.
[34] G. Moretto,et al. Tumor Necrosis Factor α and Human Schwann Cells: Signalling and Phenotype Modulation Without Cell Death , 2000, Journal of neuropathology and experimental neurology.
[35] R. Kikkawa,et al. Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves , 2000, Journal of the Neurological Sciences.
[36] H. Sano,et al. Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. , 1999, Biochemical and biophysical research communications.
[37] N. Hotta,et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.
[38] A. Schmidt,et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.
[39] J. Wautier,et al. [Pathophysiologic aspects of diabetic angiopathy]. , 1999, Diabetes & metabolism.
[40] P. Guillausseau,et al. Diabetes, advanced glycation endproducts and vascular disease , 1998, Vascular medicine.
[41] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[42] A. Schmidt,et al. Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.
[43] P. Guillausseau,et al. Rapid Publication , 1971, Nature.
[44] John G Flanagan,et al. Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map , 1995, Cell.
[45] G. Otto,et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.
[46] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[47] Y. Zou,et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.
[48] D. Zochodne,et al. Normal blood flow but lower oxygen tension in diabetes of young rats: microenvironment and the influence of sympathectomy. , 1992, Canadian journal of physiology and pharmacology.
[49] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.
[50] M. Bitensky,et al. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.